Stellantis Trails Its Rival on Key Metrics but Offers Compelling Upside for Patient Investors

Stellantis is down nearly 47% over the past year after a major earnings collapse in 2025: revenue fell 2.1%, while profit swung from a 2024 gain of €5.5B to a 2025 loss of €22.4B (−€7.75/share). The article notes dividend suspension versus GM’s 20% dividend hike (from $0.15 to $0.18/quarter) and links pressures to 2025 inflation, interest rates, and tariffs. Near-term, Q1 2026 sales rose 6.4% and EPS came in at €0.14 ($0.16), beating estimates, with management’s turnaround plan targeting earnings recovery toward 2027 ($0.85) and 2028 ($1.76), implying potential double-digit price upside if execution holds.

Analysis

STLA is being priced like a balance-sheet repair story, not a normal cyclical recovery, which means the equity can re-rate fast only if management proves that margin restoration is durable rather than a one-quarter bounce. The important mechanism is leverage: in autos, a small improvement in mix, incentives, and plant utilization can expand EBIT sharply, but the reverse is also true if pricing slips again. That makes this less about revenue growth and more about whether cost cuts survive the next demand wobble.

Relative to GM, the market is giving more credibility to a cleaner earnings bridge and capital-return visibility. If STLA’s turnaround works, the second-order winners are not just shareholders but also its tier-1 suppliers and dealers, because a successful reset usually means higher production cadence and less end-market discounting; if it fails, the pain will show up first in Europe-linked volume and parts demand, then in any supplier tied to Jeep/Ram-heavy inventory cycles. The implied recovery path also leaves little room for another tariff or interest-rate shock, since autos are one of the fastest sectors to feel consumer financing stress.

The contrarian point is that consensus may be too focused on headline earnings targets and not enough on cash conversion. Auto turnarounds often look cheap on forward EPS long before the free-cash-flow math works, especially if restructuring, warranty, and capex stay elevated. The next 1-3 month catalyst is guidance; the 6-18 month catalyst is whether operating margins can normalize without relying on a benign macro backdrop.

Key Decisions for Investors

• Prefer a relative-value long GM / short STLA pair over the next 1-3 months; GM has clearer capital-return support and less turnaround execution risk, while STLA’s upside depends on multiple things going right at once.
• Do not buy STLA outright ahead of the next earnings/guidance update; wait for proof that operating margin and free cash flow are inflecting, not just that unit sales stabilized.
• If STLA reports another miss or trims 2026 margin guidance, use that as an invalidation trigger for any bullish thesis; the stock can re-rate back toward distressed multiples quickly on a single negative reset.
• For tactical exposure only, consider a small long-dated STLA call spread after a confirmed positive guidance revision; the stock is cheap enough that convexity is preferable to stock ownership, but only with confirmation.
• Monitor F and GM supplier-chain commentary for second-order effects: if STLA volume normalization forces stronger discounting or parts demand reacceleration, it can compress margins across the legacy auto complex.